VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTI BODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the recombinant fully human anti-ActRIIA/IIB monoclonal antibody drug (JMT206) (the ‘‘Product ’’) developed by the Group has obtained approval from the National Medical Products Admin istration of the People ’s Republic of China to conduct clinical trials in China. The Product can simultaneously and specifically bind to act ivin receptor type IIA (ActRIIA) and type IIB (ActRIIB), and block the binding of activin A, myostatin (GDF8) and growth differentiation factor 11 (GDF11) to activin type II receptor (ActRII), thereby inh ibiting downstream signaling pathway activation, reducing muscle loss and promoting the mainten ance and growth of skeletal muscle to achieve the effect of increasing muscle mass and reducing fa t. Meanwhile, the Product can also enhance the quality of weight loss outcomes achieved with GL P-1 receptor agonists. The indication for this clinical trial approval is weight management for indiv iduals with obesity or overweight and at least one weight-related comorbidity. Preclinical studies showed that the Product exhibited high bioavailability as well as favorable efficacy and safety profiles, providing a promising clinical develo pment value. By order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 26 November 2025 – 1 – As at the date of this announcement, the Board comprises Mr. C AI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bin g, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WA NG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Steph en and Ms. LI Quan as Independent Non-executive Directors. – 2 –

The release as fetched from its publisher. irasia.com ↗